How'd you fix Olive AI's revenue issues in 2026?

Direct Answer

Olive's 2026 resurrection requires surgical focus: abandon horizontal RCM-for-everyone, build a vertical-first play for *one* hospital network type (health systems under 100 beds), drop 80% of the feature matrix, ship agentic RPA + ambient scribing as a bundled pair, and move from implementation-heavy services to self-serve SaaS motion within 18 months.

What's Actually Broken

1. Overpromise collapse: Olive positioned as "AI workforce" but was 60-70% manual human fixes. Hospitals caught the gap → trust vaporized → contractual exits spiked.

1. Scope creep vs. focus: Pivoted 27 times, chased RCM + prior auth + patient access + claims + eligibility simultaneously. Tried to boil the ocean. Notable Health, Tennr, Athelas each own *one* vertical (admin, referral docs, full stack) → cleaner narrative, faster ROI.

1. Revenue commodity trap: By 2023, hospital RCM automation became table-stakes. Waystar absorbed Olive's clearinghouse IP for $10M (vs. $4B valuation myth). Athelas, Tennr, and UiPath-backed RPA shops commoditized the value-per-dollar.

1. Services model asphyxiation: Implementation-heavy, 18-month sales cycles, $2-5M ASP with 35% gross margins. Burned $800M on slow ramp, couldn't reach profitability at blended unit economics.

1. Competitive moat gone: Waystar + Humata + Athelas now own the assets. Prior auth sold to Humata ($1.25M). RCM went to Waystar. Anterior, Notable, and Tennr each claimed a wedge. No defensible TAM left for legacy Olive.

The 2026 Fix Playbook

1. Vertical Narrowing

• Pick: Critical access hospitals (CAHs) + 50-99 bed rural health systems. 6,000+ units in US, 80% manual RCM, zero Athelas/Tennr penetration.
• Rationale: Athelas targets health systems 200+. Tennr focuses referral intake. CAHs need 3-5 FTE equivalency at $180-250K all-in. Olive's $500K entry + 12-month payback is 2.5x margin vs. large health system compression.

2. Agentic Doubling (Ambient + RPA)

• Ship ambient clinical scribing (auto-chart from provider voice) + agentic RPA layer (autonomous denials appeals, prior auth callback loops, eligibility pings).
• Rationale: Athelas launched integrated EHR+agents July 2025. Olive 2026 reboot can't compete on full stack but *can* own the ambulatory + back-office bundle.
• Use Claude/Anthropic extended thinking for complex prior auth rule engines instead of brittle BPMN scripts.

3. SaaS GTM Pivot

• Move from implementation services ($2-5M deals / 18 months) → self-serve onboarding (Zapier/Make.com for referral/auth flows) + low-touch SaaS ($300-600/user/month).
• Target: 50-hospital customer base @ $500K ARR by month 24 (vs. 10 hospitals @ $3M ASP = same revenue, 100x margin).

4. Partner Up the Stack

• OEM Athelas Air EHR for scribing layer (don't build). License Notable Health's intake automation for patient-facing workflows. Land UiPath's dev community for custom RPA on top.
• Rationale: Olive's $902M burn taught: don't own every layer. Partnerships → faster ship, 40% lower CAC.

5. One New Angle: Payer AI Agents

• Launch Denials AI Agents (agentic outbound calls to payers for claim status). Athelas can call; Olive can automate the conversation tree, dispute logic, and escalation.
• Market: Hospital CFOs pay $500-1000/appeal for manual labor. Agent @ $0.50/appeal = instant ROI.
• Competitive gap: No one else owns the "agentive payer interaction" space yet.

Bottom Line

Olive failed because it tried to own horizontal RCM commoditized by Waystar/Athelas/Tennr while bleeding $800M on services. 2026 resurrection lives in *vertical focus* (CAHs), *agentic differentiation* (denials agents nobody else ships), and *SaaS economics* (self-serve onboarding, 75%+ GM, no implementation overhead). TAM is smaller ($200M vs. $4B fantasy) but defensible, profitable by month 18, and free of the overpromise narrative that killed credibility.